|
Development of a bispecific tetravalent CD33/CD3 TandAbfor the treatment of AML. |
|
|
Employment - Affimed Therapeutics |
|
|
Employment - Affimed Therapeutics |
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics |
|
|
Employment - Affimed Therapeutics |
Patents, Royalties, Other Intellectual Property - GANYMED Pharmaceuticals |
|
|
|
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics |
|
|
Employment - FoxBiopharma; Sunesis Pharmaceuticals |
Leadership - FoxBiopharma; Sunesis Pharmaceuticals |
Stock and Other Ownership Interests - Amphivena Therapeutics; Sunesis Pharmaceuticals |
Consulting or Advisory Role - Amphivena Therapeutics; Sunesis Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - Sunesis Pharmaceuticals |
|
|
Employment - Affimed Therapeutics |
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics |
|
|
Employment - Affimed Therapeutics |
|
|
Employment - Affimed Therapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Affimed Therapeutics |
Stock and Other Ownership Interests - CT Atlantic |
Patents, Royalties, Other Intellectual Property - CT Atlantic AG |